VEGFA and neoplasm: The MVD of the AAV2‐VEGF‐Trap group and AAV2‐VEGF‐Trap combined with the paclitaxel group were significantly lower than that of control group and paclitaxel group (Figure 2A,B), indicating that AAV2‐VEGF‐Trap can effectively inhibit tumor neovascularization in TNBC.